AI Tool Enhances Accuracy in Predicting Patient Response to Cancer Immunotherapy Drugs

Oh, brilliant. COMPASS. Because when you're facing a cancer diagnosis, what you really need is another acronym promising to navigate the treacherous waters of immunotherapy response prediction. The model, we're told, "sets a new standard" by analyzing tumor gene expression data to improve accuracy. Translation: it's slightly less useless than whatever came before.

Let's examine the claim with the cynical precision it deserves. Any tool that can better identify the lucky few is potentially valuable. Without numbers, it's marketing, not science.

Remember IBM Watson for oncology? That was going to set a new standard too. COMPASS may be different, but we've been burned before. The AI hype cycle in medicine is a well-worn path: initial excitement, funding, press coverage, then gradual disillusionment as the model fails to generalise. COMPASS could break the cycle, but I'll believe it when I see it in a Lancet paper. Until then, it's just another compass pointing in a direction we've heard before.